Myeloma Crowd Radio: Frank Zhan, PhD and Yogesh Jethava, MD, University of Iowa
Targeting CD24 to Eliminate Myeloma Stem Cells
Myeloma stem cells (or early progenitor cells before they become plasma cells) may not be killed with current myeloma therapies and could be the cause of relapse. Dr. Zhan has identified the presence of CD24 as a strong candidate as a cancer stem cell marker and believes that high CD24 levels lead to more aggressive myeloma and earlier death. His work will test patient samples for the presence of CD24 and assess outcomes while also identifying CD24 monoclonal antibodies that could impact this target. Learn more from Dr. Zhan and Dr. Yogesh Jethava of the University of Iowa in this Myeloma Crowd Research Initiative show. Donate to the MCRI here: give.crowdcare.org/mcri
Thanks to our episode sponsor, Celgene Corporation.